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Summary
 
Epstein-Barr virus (EBV), a human 
 
g
 
-herpesvirus, can establish both nonproductive (latent)
and productive (lytic) infections. Although the CD8
 
1
 
 cytotoxic T lymphocyte (CTL) response
to latently infected cells is well characterized, very little is known about T cell controls over
lytic infection; this imbalance in our understanding belies the importance of virus-replicative
lesions in several aspects of EBV disease pathogenesis. The present work shows that the primary
CD8
 
1
 
 CTL response to EBV in infectious mononucleosis patients contains multiple lytic anti-
gen-specific reactivities at levels at least as high as those seen against latent antigens; similar re-
activities are also detectable in CTL memory. Clonal analysis revealed individual responses to
the two immediate early proteins BZLF1 and BRLF1, and to three (BMLF1, BMRF1, and
BALF2) of the six early proteins tested. In several cases, the peptide epitope and HLA-restrict-
ing determinant recognized by these CTLs has been defined, one unusual feature being the
number of responses restricted through HLA-C alleles. The work strongly suggests that EBV-
replicative lesions are subject to direct CTL control in vivo and that immediate early and early
proteins are frequently the immunodominant targets. This contrasts with findings in 
 
a
 
- and
 
b
 
-herpesvirus systems (herpes simplex, cytomegalovirus) where viral interference with the anti-
gen-processing pathway during lytic infection renders immediate early and early proteins much
less immunogenic. The unique capacity of 
 
g
 
-herpesvirus to amplify the viral load in vivo
through a latent growth-transforming infection may have rendered these agents less dependent
upon viral replication as a means of successfully colonizing their hosts.
 
E
 
pstein-Barr virus, a 
 
g
 
-herpesvirus widespread in hu-
man populations, is carried as a life-long infection in
the great majority of immunocompetent individuals (1).
Viral infection and persistence are accomplished through a
balance of productive (lytic) and nonproductive (latent) in-
fections. After oral transmission, a primary focus of virus
replication is established in oropharyngeal epithelium (2)
and/or local mucosa-associated lymphoid tissue (3), with in-
fectious virus being shed into the throat. At the same time,
the virus colonizes the generalized B cell pool through a la-
tent growth-transforming infection (4), thereby establishing
a reservoir of virus genome-positive cells upon which long-
term virus persistence depends (5, 6). Subsequent reactiva-
tion of such B cells from latency into lytic cycle can then
initiate secondary foci of virus replication at pharyngeal sites.
There is strong evidence that the size of the latently in-
fected B cell pool is kept under control by host CD8
 
1
 
 CTL
responses both during primary infection (7) and through-
out the life-long carrier state (8, 9). However, despite the
likely importance of virus replicative lesions in several as-
pects of EBV-associated disease pathogenesis (10–13), vir-
tually nothing is known about T cell controls which might
be exercised over lytic infections. This contrasts with the
situation for herpesviruses of the 
 
a
 
 and 
 
b
 
 subfamilies, such
as HSV and CMV, where lytic antigen-specific CD8
 
1
 
CTL responses have been detected (14–16). Interestingly,
these tend to be directed not against immediate early or
early antigens of the lytic cycle, but against some of the vi-
rus structural proteins that are delivered into the cell by the
incoming virus particle (15, 17); this focusing of the re-
sponse on preformed antigens reflects the fact that some of
the first viral proteins to be expressed de novo in HSV- or
CMV-infected cells actually inhibit the pathway of antigen
presentation to CD8
 
1
 
 lymphocytes (15, 17–22). Whether a
similar situation pertains with EBV is therefore of particular
interest.
The current imbalance in our understanding of EBV-
induced CTL responses reflects the fact that latent infec-
tions of B lymphocytes can readily be established in vitro in
the form of virus-transformed lymphoblastoid cell lines
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(LCLs)
 
1
 
 expressing the full range of virus latent proteins,
namely, the EB nuclear antigens (EBNAs) 1, 2, 3A, 3B, 3C,
-LP, and the latent membrane proteins LMPs 1 and 2 (1).
By contrast, no naturally permissive system for EBV repli-
cation exists in vitro and so studies of lytic cycle have had
to focus on the small numbers of cells within LCLs which
activate virus replication either spontaneously or after treat-
ment with inducing agents (23). Co-cultivating T cells
from an immune individual with autologous LCL stimula-
tors has made possible a quite detailed analysis of latent cy-
cle-specific CTL responses across a wide range of HLA
class I restriction elements and has shown an unusually
marked focusing of responses on immunodominant epitopes
from the EBNA3A, 3B, 3C subset of latent proteins (8, 9,
24). To date, however, such in vitro reactivation protocols
have not revealed obvious lytic cycle-specific components
of the response.
In the present study, we have addressed the question of
lytic antigen-specific reactivities in another way. The work
was prompted by our recent observation that the circulat-
ing CD8
 
1
 
 T cells of infectious mononucleosis (IM) patients
undergoing primary EBV infection contained a variety of
latent cycle-specific effectors which were not only detect-
able in ex vivo cytotoxicity assays using antigen- or peptide
epitope-sensitized targets, but also could be separated into
individual reactivities by limiting dilution cloning in vitro
(7). The efficiency of the system suggested to us that any
co-resident lytic cycle-specific effectors should also be de-
tectable using such an approach. As with other herpesvi-
ruses, EBV replication is associated with the expression of a
large number of (up to 80) lytic cycle proteins which can
be classified into three temporal phases; immediate early,
early, and late (23). Here we focused our attention on the
two best known EBV immediate early proteins, BZLF1
and BRLF1 (25, 26), and on six representative early pro-
teins, BMLF1, BMRF1, BHLF1, BHRF1, BALF2, and
BALF5, several of which are directly transactivated by
BZLF1/BRLF1 during the progress of the lytic cycle (27–
29). The initial stages of the work were greatly assisted by
an observation from Bogedain et al. (30) who used pooled
peptides from the BZLF1 sequence as an in vitro stimulus
to T cells from virus-immune donors and in that way iden-
tified a 8-mer BZLF1 peptide RAKFKQLL that appeared
to be recognized by HLA-B8–restricted memory CTLs.
This remains the only indication in the literature that EBV
lytic infections might induce a CD8
 
1
 
 T cell response. Here
we show that EBV infection induces abundant CTL reac-
tivities to a range of immediate early and early lytic cycle
proteins.
 
Materials and Methods
 
Donors.
 
Six IM patients, identified on clinical grounds and by
heterophile antibody positivity, were sampled during the first 10 d
of illness and, in some cases, on a second occasion 9–21 mo after
the resolution of symptoms. Two healthy virus carriers, CG and
KG, were also studied. The donors were HLA typed either by
serotyping in microcytotoxicity assays (lymphotype AB120; Bio-
test, Denville, NJ) or by genotyping (courtesy of Dr. M. Hatha-
way, Liver Laboratories, University of Birmingham, Birming-
ham, U.K.). The HLA-A, -B, and, where appropriate, -C types
were as follows. IM53: A3, A30, B8, B18, C5, C7; IM55: A24,
A32, B13, B60, C3, C6; IM59: A1, A2, B8, B62; IM61: A2.01,
A3, B7, B44, C5, C7; IM63: A1, A2.05, B8, B49, C6, C7;
IM69: A2.01, A32, B7, B63; KG: A30, A32, B44, B47, C5, C6;
CG: A25, A28, B39, B62.
 
LCL Establishment and Preparation of CTL Effectors.
 
Heparinized
whole blood (50 ml) was diluted 1:1 in RPMI 1640 medium and
separated by centrifugation on lymphoprep (Nycomed Pharma,
Oslo, Norway). Peripheral blood mononuclear cells (PBMCs) were
harvested from the interface, washed, and cryopreserved within
3 h of venesection. Aliquots of PBMCs were used for the estab-
lishment of an EBV-transformed LCL either by spontaneous trans-
formation with the donor’s own virus strain or by addition of ex-
ogenous EBV (B95.8 strain); for this, the culture medium was
RPMI 1640 
 
1
 
 2 mM glutamine 
 
1
 
 10% vol/vol FCS, initially
supplemented with 0.1 
 
m
 
g/ml cyclosporin A. The proportion of
cells spontaneously entering lytic cycle in such lines was deter-
mined by indirect immunofluorescence staining using the BZLF1-
specific mAb BZ-1 (31) and the virus capsid antigen–specific
mAb V3 (32).
Acute IM PBMC effectors for use in ex vivo cytotoxicity as-
says were thawed in IL-2–enriched medium (see below) and used
either directly or after initial depletion of CD16
 
1
 
 NK cells. For the
latter, PBMCs were incubated for 30 min at 4
 
8
 
C with 5 
 
m
 
l anti-
CD16 IgM mAb (leu 11b; Becton Dickinson, San Jose, CA)/10
 
6
 
cells, washed once, and incubated for 1 h at 37
 
8
 
C in IL-2–enriched
medium containing 5:1 vol/vol rabbit complement (C0999f; Har-
lan Sera-Lab, Loughborough, U.K.), and then washed twice before
use in the cytotoxicity assay.
Primary polyclonal CTL lines were established by stimulating
thawed IM PBMCs on day 0 and weekly thereafter with the au-
tologous LCL at an effector/stimulator ratio of 4:1 in RPMI 1640
 
1
 
 2 mM glutamine 
 
1
 
 10% vol/vol FCS, 1% vol/vol human se-
rum, 30% vol/vol supernatant from the IL-2–secreting cell line
MLA-144 (MLA-SN), and 100 U/ml of recombinant IL-2 (here-
after called IL-2–enriched medium). Primary CTL clones were
established by limiting dilution of thawed IM PBMCs directly
into IL-2–enriched medium at 0.3–100 cells/0.2 ml round-bot-
tomed well in the presence of irradiated preactivated allogeneic
PBMC feeders (10
 
6
 
/ml) either alone, with irradiated autologous
LCL cells (10
 
5
 
/ml), or with the addition of the anti-CD3 mAb
(OKT3; Unipath, Basingstoke, U.K.) to a final concentration of
50 ng/ml. In each case, growing microcultures were further ex-
panded by transfer into 2-ml wells using the same stimulation
protocol as before. Feeder cells were from pooled fresh buffy
coats (National Blood Service, Birmingham, U.K.) and were in-
cubated with PHA at 10 
 
m
 
g/ml for 1 h, and then washed five
times before irradiation and use. In some cases, CTL clones were
also established from 14-d cultures of the polyclonal CTL line or
from limiting dilution cultures by reseeding at 0.3–3 cells/well
using the conditions outlined above. Memory CTL clones were
established as previously described (33). In brief, PBMCs from
postconvalescent IM donors or from long-term virus carriers
were stimulated with the autologous LCL at a responder/stimula-
tor ratio of 40:1, and then restimulated 10 d later at a responder/
stimulator ratio of 4:1. Cloning took place 4 d later by seeding at
 
1
 
Abbreviations used in this paper:
 
 EBNA, EB nuclear antigen; IM, infectious
mononucleosis; LCL, lymphoblastoid cell line; TK, thymidine kinase;
vacc, vaccinia. 
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0.3–3 cells/well using the conditions outlined above. All primary
and memory CTL clones were screened for CD4 and CD8 ex-
pression by indirect immunofluorescence staining using the
CD4-specific mAb 716 and the CD8-specific mAb 707 (Dako,
High Wycombe, U.K.).
 
Vaccinia Recombinants and Plasmid Expression Vectors.
 
Recom-
binant vaccinia viruses expressing the EBV immediate early pro-
teins BZLF1 and BRLF1, and the early proteins BHRF1 and
BMLF1 have been described previously (34); note that the vac-
cinia-BMLF1 (vacc-BMLF1) recombinant expresses a truncated
form of BSLF2/BMLF1 protein which lacks NH
 
2
 
-terminal se-
quences provided by the small BSLF2 exon. Recombinants ex-
pressing the early proteins BMRF1, BHLF1, BALF2, and BALF5,
and the late proteins BCRF1 and BLLF1, were generated as be-
fore by insertion of the relevant coding sequence into the vac-
cinia thymidine kinase (TK) gene locus under the control of the
vaccinia P7.5 early–late promoter; vacc-TK
 
2
 
 is a control recom-
binant lacking an inserted sequence. A second independently con-
structed vacc-BZLF1 recombinant was provided by Dr. M. Mack-
ett (Paterson Institute for Cancer Research, Manchester, U.K.).
All vaccinia recombinants were used to infect target cells (LCLs,
fibroblasts, or SV40-transformed keratinocytes) at a multiplicity of
infection of 10:1 followed by overnight incubation as described
(8) and inclusion in a standard 5–7 h chromium release assay.
BZLF1 was also expressed in SV40-transformed keratinocyte
targets by transient transfection of the plasmid vector pSG5 (Strat-
agene Ltd., Cambridge, U.K.) carrying a BZLF1 gene insert (pSG5-
BZLF1); pSG5 itself and the equivalent pSG5-EBNA1 construct
served as controls. For transfection, the adherent target cells were
washed twice in DME and then incubated for 2 h at 37
 
8
 
C in
2.5 ml DME containing chloroquine (0.8 mM), DEAE dextran
(0.4 mg/ml), and 10 
 
m
 
g plasmid DNA. The cells were then incu-
bated for 2 min in phosphate-buffered saline containing 10% vol/
vol DMSO, washed twice, and then incubated in DME 
 
1
 
 10%
vol/vol FCS for 48 h before inclusion in a standard cytotoxicity
assay. Expression of BZLF1 was again monitored by indirect im-
munofluorescence staining with mAb BZ-1.
 
Peptides.
 
Peptides were synthesized by standard fluorenyl-
methoxycarbonyl chemistry (Alta Bioscience, University of Bir-
mingham), dissolved in DMSO, and their concentrations deter-
mined by biuret assay. Target cells in peptide sensitization assays
were T lymphoblasts which had been expanded in vitro in IL-2–
enriched medium for at least 2 wk after initial PHA stimulation;
such cells were incubated with appropriate concentrations of pep-
tide (or with dilutions of DMSO solvent as a control) for 1 h
before inclusion in a standard cytotoxicity assay. Where large
numbers of overlapping peptides were to be screened for epitope
location, CTL recognition was monitored using a direct visual as-
say of T cell–T cell killing (35).
 
Results
 
Recognition of the BZLF1 190-197 Peptide Epitope by IM
Effectors Ex Vivo.
 
The initial series of experiments specifi-
cally focused on IM patients with an HLA-B8 allele to
check for recognition of the reported B8 epitope peptide
BZLF1 190-197 in cytotoxicity assays using IM effectors
prepared immediately ex vivo. Since HLA-B8 is also known
to present two immunodominant epitopes from the latent
cycle protein EBNA3A, namely 158-166 and 325-333 (36,
37), these peptides were included as reference epitopes in
the same assays. Cryopreserved PBMCs from three HLA-
B8–positive patients, IM53, IM59 and IM63, were thawed
into IL-2–enriched medium and used immediately as effec-
tors in 7 h chromium release assays against autologous PHA
blast targets that had been preexposed to the relevant
epitope peptides. The results are shown in Fig. 1, 
 
A–C.
 
There was clear recognition of both the reference latent cy-
Figure 1. Screening of IM
primary effectors immediately
ex vivo (A–C) and after LCL
stimulation in vitro and expan-
sion to a polyclonal CTL line
(D–F). Epitope-specific reactivi-
ties were detected using autolo-
gous PHA blast targets pretreated
with the denoted epitope pep-
tides at 2 mg/ml or with an
equivalent concentration of
DMSO solvent alone (“no pep-
tide” control). Results are ex-
pressed as percentage specific ly-
sis in 7-h chromium release
assays for (A) IM53 effectors
tested ex vivo at E/T ratios of
60:1 (j) and 30:1 ( ); (B)
IM59 effectors tested ex vivo at
E/T ratios of 80:1 (j), 40:1 ( ),
and 20:1 ( ); (C) IM63 effec-
tors tested ex vivo at E/T ratios
of 70:1 (j), 30:1 ( ), and 15:1
( ); (D) IM53 CTL line at E/T
ratios of 10:1 (j) and 5:1 ( );
(E) IM59 CTL line at E/T ratios
of 10:1 (j) and 5:1 ( ); and (F)
IM63 CTL line at E/T ratios of
20:1 (j) and 10:1 ( ). 
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cle EBNA3A epitopes by effectors from IM59 and IM63,
and of the EBNA3A 325-333 epitope by IM53, confirm-
ing patterns of lysis already described in earlier studies with
cryopreserved effectors from these particular patients (7).
More importantly, however, all three individuals showed
even stronger recognition of targets preloaded with the
BZLF1 190-197 peptide. Levels of lysis clearly above back-
ground were detectable at effector/target ratios from 80:1
down to as low as 15:1; note that primary CTL reactivities
against immunodominant latent cycle epitopes frequently
became undetectable at this lower ratio (e.g., Fig. 1 
 
C
 
 and
reference 7). Subsequent work confirmed that this recogni-
tion of the BZLF1 peptide was reproducible in repeat as-
says and was restricted to HLA-B8–positive targets (data
not shown).
 
In Vitro Expansion of BZLF1 190-197–Reactive CTLs.
 
We had previously established autologous LCL stimulation
protocols that allowed latent antigen-specific CTLs within
the IM T cell population to be expanded in vitro either as
short-term bulk polyclonal lines or as limiting dilution clones.
Screening LCL cultures that had been established by spon-
taneous in vitro transformation from the above IM patients
identified up to 5% cells expressing the BZLF1 immediate
early protein and up to 2% cells positive for the late lytic
cycle marker virus capsid antigen. Such autologous LCLs
were therefore used as a source of EBV lytic antigen-posi-
tive stimulators in an effort to expand the above BZLF1
epitope-specific CTLs in vitro.
In the first instance, thawed IM effectors were expanded
as short-term bulk cultures in IL-2–enriched medium with
immediate autologous LCL stimulation, and assayed for cy-
totoxic activity against peptide-loaded target cells after two
weeks. The results thus obtained from the same three indi-
viduals, IM53, IM59, and IM63, are shown in Fig. 1, 
 
D–F.
 
In each case, effectors specific for the BZLF1 190-197 epi-
tope were detectable in the in vitro–expanded populations,
here tested at effector/target ratios between 20:1 and 5:1.
However, the overall pattern of results indicates that these
effectors had not been expanded as efficiently as the latent
cycle-specific CTLs. This is particularly apparent for IM53,
where in vitro expansion had maintained the original
EBNA3A 325-333 reactivity and now also revealed an
EBNA3A 158-166 reactivity which had been below the
level of detection in ex vivo assays; by contrast, the BZLF1
190-197 reactivity was now comparatively weak (Fig. 1, 
 
A
 
and 
 
D
 
).
Our recent work studying latent cycle specificities within
IM T cell preparations had indicated that low abundance
CTLs could be separated from immunodominant com-
ponents by limiting dilution cloning in IL-2–conditioned
medium on a combination of autologous LCL cells and
pooled allogeneic PBL feeders (7). We therefore adopted
this same approach in an effort to isolate CTLs specific for
the BZLF1 190-197 epitope away from the co-resident la-
tent cycle-specific reactivities. Cryopreserved ex vivo ef-
fector populations from reference donors IM53 and IM59
were seeded at 30–100 cells/well, and all wells showing
successful T cell outgrowth were screened for epitope-spe-
cific reactivities. These experiments showed that 30–60%
of growing wells contained BZLF1 epitope-specific CTLs;
this was at least as high as the proportion of wells with
EBNA3A reactivity in each experiment (assayed using pep-
tide 325-333 for IM53 and peptide 158-166 for IM59) and
in many instances, the BZLF1 and EBNA3A epitopes reac-
tivities were now present in separate wells. In further assays
of cloning strategies using ex vivo effectors from IM63, we
found that the BZLF1 epitope-specific CTLs (and other
lytic cycle reactivities, see later) could be expanded almost
as efficiently with the CD3-specific mAb OKT3 as a stimu-
lus as with the autologous LCL. In subsequent experiments,
therefore, we used the two methods of stimulation in paral-
lel. Both yielded limiting dilution clones which could be
maintained for several weeks in IL-2–conditioned medium
with appropriate stimulation and which could be sub-
cloned, if necessary, to check specificity.
 
Confirmation of BZLF1 Antigen Specificity.
 
Fig. 2 
 
A
 
 shows
data from a representative BZLF1 epitope-specific clone,
IM63 c34, obtained as described by limiting dilution cul-
ture of IM63 PBMCs ex vivo. The results illustrate an un-
usual feature of the BZLF1 190-197 epitope-specific re-
sponse that we consistently observed with cloned effectors
from IM53, IM59, and IM63. These CTLs efficiently rec-
ognized autologous and HLA-B8–matched target cells
when they were preloaded with the relevant epitope pep-
tide, but not when they were infected with a recombinant
vaccinia vector expressing the full length BZLF1 protein.
We made the same observation using two independently
constructed vacc-BZLF1 recombinants and three different
types of target cells (LCLs, fibroblasts, keratinocytes) in as-
says where efficient expression of BZLF1 in the vaccinia-
infected targets was confirmed by immunofluorescence stain-
ing. To check whether BZLF1 could ever be processed to
generate the 190-197 epitope, the experiments were ex-
tended to include a B8-positive keratinocyte line in which
BZLF1 expression could be achieved in up to 40% cells by
transient transfection with a plasmid vector. CTL clones
such as IM63 c34 now showed clear recognition not only
of the 190-197 peptide, but also of the BZLF1-positive tar-
gets (Fig. 2 
 
A
 
). We then went back to cryopreserved ex
vivo effectors from IM63 and also from IM59, to carry out
this same type of assay. As shown in Fig. 2, 
 
B
 
 and 
 
C
 
, these
primary cells were also found to recognize target cells ex-
pressing BZLF1 from the transiently transfected plasmid
vector, but not targets infected with the vacc-BZLF1 re-
combinant. We infer that the above effectors are indeed re-
active to the immediate early protein BZLF1 and that pro-
cessing of the 190-197 epitope is somehow impaired in
vaccinia-infected cells.
 
Identification of Additional Subdominant Reactivities to Early
Lytic Proteins Alongside the BZLF1 Response.
 
Having estab-
lished limiting dilution conditions capable of expanding the
BZLF1-specific T cells from B8-positive IM patients, the
work was extended to look for CTL reactivities to other lytic
cycle antigens. It seemed to us most unlikely that the pro-
cessing and presentation of lytic cycle epitopes would be
generally impaired in the vaccinia system and we therefore 
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elected to screen IM-derived limiting dilution cultures on
autologous LCL targets infected with one of a panel of vac-
cinia recombinants expressing the immediate early proteins
BZLF1 and BRLF1, the early proteins BMLF1, BMRF1,
BHLF1, BHRF1, BALF2, and BALF5, and the late pro-
teins BCRF1 and BLLF1.
Two of the original patients, IM63 and IM53, were stud-
ied in this way and both revealed additional lytic antigen-
specific CTL reactivities that were less abundant than the
HLA-B8–restricted BZLF1 response, but were nevertheless
detectable by limiting dilution cloning. For IM63, there
were two such reactivities (Fig. 3). One, exemplified by
Figure 2. Screening of BZLF1 190-197 epitope-specific effectors for
recognition of targets expressing the BZLF1 protein. Assays were con-
ducted on autologous PHA blast targets pretreated with the BZLF1 190-
197 peptide at 2 mg/ml or with an equivalent concentration of DMSO
alone (“no peptide” control), and on HLA-B8–matched keratinocyte or
fibroblast targets infected with vacc-BZLF1 or with vacc-TK2 as a con-
trol, or transiently transfected with pSG5-BZLF1 or with pSG5 as a con-
trol. Results are expressed as in Fig. 1 for (A) IM63 primary clone 34 es-
tablished by limiting dilution cloning of IM63 effectors ex vivo and tested
at a E/T ratio of 5:1, and for (B) IM63 ex vivo effectors and (C) IM59 ex
vivo effectors, both tested at E/T ratios of 80:1 (j) and 40:1 ( ).
Figure 3. Cytotoxicity testing of CTL clones established by limiting
dilution cloning of IM63 effectors ex vivo. Analysis of (A) IM63 primary
clone 70 and (B) IM63 primary clone 9.1 for HLA restriction by screen-
ing on the autologous LCL and on a panel of allogeneic LCLs infected
with (A) vacc-BMLF1 and (B) vacc-BMRF1. For each allogeneic LCL
target, the HLA class I alleles shared with IM63 are indicated; note that in
(A) the A1- and the C6-matched targets also express HLA-A2.01, indi-
cating that this A2.05-restricted CTL clone cannot use A2.01 as a restric-
tion element. (C) Analysis of IM63 primary clone 9.1 for peptide epitope
specificity by screening on autologous PHA blast targets pretreated with
the following BMRF1 peptides at 1025 to 10212 M concentrations;
BMRF1 267-276 (r), 267-275 (,), 268-277 (e), 268-276 (.), and
269-276 (d). Results are expressed as in Fig. 1 and all assays were con-
ducted at an E/T ratio of 5:1. 
1610
 
CTL Responses to Epstein-Barr Virus Lytic Cycle Antigens
 
IM63 c70, showed specific recognition of BRLF1 in re-
combinant vaccinia assays and, when tested on a range of
vacc-BRLF1–infected allogeneic LCLs each sharing a sin-
gle HLA allele with IM63 (HLA-A1, A2.05, B7, B49, C6,
C7), was found to be restricted through HLA-A2.05 (Fig.
3 
 
A
 
). The other reactivity, exemplified by IM63 c9.1, was
directed against BMRF1 and was restricted through HLA-
C6 (Fig. 3 
 
B
 
). These BMRF1-specific effectors were then
screened on autologous PHA blast targets preexposed to
individual peptides (15 mer overlapping by 10) from a
panel which covered the entire primary sequence of the
BMRF1 protein. Using a visual assay of T cell–T cell kill-
ing, this screening showed recognition of a single peptide
BMRF1 266-280. Subsequent titration of 9- and 10-mer pep-
tides within this region in standard chromium release assays
identified the sequence YRSGIIAVV (BMRF1 268-276)
as the minimal HLA-C6–restricted epitope (Fig. 3 
 
C
 
); this
accords well to the consensus sequence proposed for C6-
binding peptides based on peptide elution (38). Note that
subsequent ex vivo assays on cryopreserved effectors from
IM63 did not show detectable reactivity against BMRF1
268-276 (data not shown), again indicating that this BMRF1
reactivity was subdominant compared to the BZLF1 re-
sponse. Extension of the work to the other patient, IM53,
revealed another novel lytic antigen-specific reactivity which
could be detected at the clonal level. A single clone from
IM53 consistently recognized vacc-BMLF1–infected cells;
assays on allogeneic LCLs matched through single HLA al-
leles with IM53-identified HLA-B18 as the restriction ele-
ment, and peptide sensitization assays identified the mini-
mal epitope as BMLF1 residues 397-405, DEVEFLGHY
(data not shown).
 
Identification of an Immunodominant HLA-A2.01–restricted
Epitope in the Early Lytic Protein BMLF1. We subsequently
went on to test a number of IM patients who did not have
the HLA-B8 allele to look for evidence of other immuno-
dominant reactivities to lytic cycle antigens. Analysis of
IM69 (HLA-A2.01, A32, B7, B63), whose predominant la-
tent antigen-specific response had earlier been mapped to the
HLA-B7–restricted epitope EBNA3A 379-387 (7), yielded
a number of CTL clones which strongly recognized the
vacc-BMLF1–infected autologous LCL in the original
screening assays and which proved to be HLA-A2.01 re-
stricted on extension of the work to vacc-BMLF1–infected
allogeneic targets (Fig. 4 A). Peptide sensitization assays
with the BMLF1 panel of synthetic peptides first mapped
recognition to the 15-mer BMLF1 276-290 and subse-
quent assays identified the minimal epitope as BMLF1 resi-
dues 280-288, GLCTLVAML (Fig. 4 B); again, this ac-
cords well to the consensus sequence for A2.01-binding
peptides (39). In view of the number of clones from IM69
which recognized the epitope, we tested cryopreserved ef-
fectors from this individual and from a second HLA-A2.01,
B7-positive patient IM61 for evidence of BMLF1 280-
288–specific lysis in ex vivo assays. The results are shown in
Fig. 5. In both cases, the response to this A2.01-restricted
BMLF1 epitope was easily detectable in the primary CTL
population ex vivo and, in fact, appeared to be as strong as
the immunodominant latent antigen-specific response rec-
ognizing the B7-restricted EBNA3A 379-387 epitope.
Multiple Lytic Antigen-specific Reactivities in an Individual
IM Patient. Such findings suggested that one might be
able to identify strong lytic antigen-specific components of
the primary EBV-induced response by screening the pri-
mary ex vivo effectors on autologous LCL targets express-
ing individual lytic antigens from recombinant vaccinia vec-
tors. The presence of latent antigen reactivities in IM T cell
populations is a complicating factor since these will pro-
duce significant baseline levels of autologous LCL killing;
in practice, however, the levels are often sufficiently low to
allow incremental lytic antigen-specific lysis to be detected
in recombinant vaccinia assays. The point is illustrated with
reference to another IM patient, IM55 (HLA A24, A32,
Figure 4. Cytotoxicity testing of IM69 primary clone 62 established by
limiting dilution cloning of IM69 effectors ex vivo. (A) Analysis of HLA
restriction by screening on the vacc-BMLF1–infected autologous LCL
and on a panel of vacc-BMLF1–infected allogeneic LCLs sharing individ-
ual HLA class I alleles with IM69 as indicated. (B) Analysis of peptide
epitope specificity by screening on autologous PHA blast targets pre-
treated with the following BMLF1 peptides at 1025 to 10210 M concen-
trations: BMLF1 279-288 (d), 280-288 (.), and 280-289 (r). Results
are expressed as in Fig. 1 and all assays were conducted at an E/T ratio of 5:1.1611 Steven et al.
B13, B60, C3, C6), where ex vivo assays on vaccinia-
infected LCL targets clearly indicated the presence of an
immunodominant response to the BMRF1 protein and
suggested that there may also be weaker reactivities against
BRLF1, BMLF1, and BALF2 (Fig. 6 A).
Subsequent limiting dilution cloning confirmed that
these individual reactivities were indeed present. Thus, the
most frequently detectable lytic reactivity seen in the clonal
analysis was against the BMRF1 protein, as represented by
IM55 clone 112 (Fig. 6 B). These clones proved to be re-
stricted through HLA-C3 and cytotoxicity assays against
overlapping 15-mer peptides from BMRF1 identified the
epitope as lying within the region BMRF1 86-100 (data
not shown). A number of other CD81 CTL clones ob-
tained in the same experiment mapped to different individ-
ual target antigens (Fig. 6 B) and showed unique patterns of
restriction when tested on allogeneic LCL targets infected
with the relevant vaccinia recombinant. Thus, IM55 c167
recognized the early protein BMLF1 in the context of
HLA-A24, IM55 c206 recognized the early protein BALF2
in the context of HLA-C6, and IM55 c145 recognized the
immediate early protein BRLF1, but in this case limited
cell numbers precluded identification of the restriction ele-
ment.
Lytic Antigen-specific Responses Detectable in CTL Memory.
The frequency of lytic antigen-specific reactivities within
the primary response to EBV infection led us to ask whether
similar reactivities were ever detectable in CTL memory. It
is clear from the data on IM donors (Fig. 1) that autologous
LCL stimulation favors the in vitro expansion of latent, as
opposed to lytic, antigen reactivities. We nevertheless ex-
amined LCL-stimulated memory CTL preparations that had
Figure 6. Analysis of the lytic antigen-specific primary CTL response
in IM55. (A) Primary effectors, depleted of CD161 NK cells were assayed
immediately ex vivo at E/T ratios of 80:1 (j) and 40:1 ( ) against autol-
ogous LCL targets infected with vaccinia recombinants expressing indi-
vidual lytic cycle genes as indicated. (B) CTL clones established by limit-
ing dilution cloning of IM55 effectors immediately ex vivo were likewise
tested for lytic antigen specificity at an E/T ratio of 5:1. Results are ex-
pressed as in Fig. 1.
Figure 5. Screening of (A) IM69 and (B) IM61 primary effectors im-
mediately ex vivo for evidence of cytotoxicity against the HLA-A2.01–
restricted epitope BMLF1 280-288. Assays were conducted on autolo-
gous or on HLA-A2.01, B7-matched PHA blast targets pretreated with
the BMLF1 280-288 peptide, with another A2.01-restricted epitope pep-
tide LMP2 329-337, with the B7-restricted epitope peptides EBNA3A
379-387 and EBNA3C 881-891, or with DMSO alone as a “no peptide”
control. Results are expressed as in Fig. 1 and both assays were conducted
at E/T ratios of 100:1 (j) and 50:1 ( ).1612 CTL Responses to Epstein-Barr Virus Lytic Cycle Antigens
been reactivated in vitro from blood samples of IM patients
53, 59, and 63 taken 9–21 mo after the resolution of their
symptoms. These preparations were dominated by latent an-
tigen-specific reactivities (in particular the B8-restricted re-
sponses to EBNA3A epitopes); however, significant recog-
nition of the BZLF1 190-197 epitope was clearly observed
using the IM59 memory line while the borderline levels of
lysis seen in assays with the IM63 memory line led us to
examine this population further by limiting dilution clon-
ing. Of 86 clones generated, 42 were specific for one or other
of the B8-restricted epitopes in EBNA3A but 7 clearly rec-
ognized the B8-restricted BZLF1 epitope. These are repre-
sented by IM63 memory c20 (Fig. 7 A) which showed
strong lysis of BZLF1 190-197 peptide-loaded target cells
and also of B8-positive keratinocytes transiently transfected
with the BZLF1 plasmid expression vector.
Finally we went on to screen panels of limiting dilution
clones established from early passage memory CTL lines of
two long-term virus carriers. In donor KG (HLA-A30,
A32, B44, B47, C5, C6), the bulk of the LCL-reactivated
clonal response mapped to a latent cycle antigen EBNA3C.
However, 1 of the 19 clones analyzed clearly recognized
autologous targets infected with the vacc-BMLF1 recom-
binant. This CD81 clone, KG memory c19, was subse-
quently found to be specific for the 9-mer peptide epitope
BMLF1 265-273, KDTWLDARM (Fig. 7 B); the inability
to identify a restriction element for this clone (despite assays
on a range of allogeneic backgrounds) probably reflects the
fact that donor KG possesses a number of HLA alleles, in
particular A30, for which the subtypes are not yet com-
pletely defined. In a second individual, CG, the LCL-reac-
tivated CTL response was again dominated by clones reac-
tive to the latent cycle antigen EBNA3C; however, one of
the 56 EBV-specific clones established from this donor, CG
memory c14.1, consistently recognized the early lytic anti-
gen BALF2 and was restricted through HLA-B39 (Fig. 7 C).
Therefore, even using this relatively inefficient means of
CTL reactivation, lytic antigen-specific responses were de-
tectable in the CTL memory of both long-term virus carri-
ers analyzed.
Discussion
Attempts to probe the memory CTL pool of EBV carri-
ers for evidence of lytic antigen-specific responses have for
many years been frustrated by the absence of a ready source
of lytically-infected cells for use as in vitro stimulators. By-
passing the problem by stimulating with pooled peptides
(30) may well uncover isolated peptide-specific reactivities,
but cannot provide an overall picture either of the relative
frequency or of the diversity of lytic cycle responses which
an antigenically rich herpesvirus such as EBV might in-
duce. Here we describe a different experimental strategy
which has wider applicability and which exploits methods
first developed to analyze the primary CTL response to EBV
latently infected cells as seen in IM patients (7). The initial
Figure 7. Screening of memory CTL clones for lytic antigen specific-
ity. (A) IM63 memory clone 20, derived from donor IM63 9 mo after re-
covery from the primary infection, was tested against HLA-B8–matched
keratinocyte targets transiently transfected with the pSG5-BZLF1 plasmid
or with pSG5 or pSG5 EBNA1 as controls, and against autologous PHA
blast targets which had been preexposed to the BZLF1 190-197 peptide at
2 mg/ml or to DMSO alone as a no peptide control. (B) KG memory
clone 19, derived from long-term virus carrier KG, was tested against au-
tologous fibroblast targets, either uninfected or infected with the vacc-
BMLF1 or vacc-BMRF1 recombinants, and against autologous PHA blast
targets preexposed to the BMLF1 265-273 peptide at 2 mg/ml or to
DMSO alone as a no peptide control. (C) CG memory clone 14.1, de-
rived from long-term virus carrier CG, was tested against the vacc-
BALF2–infected autologous LCLs and against a range of vacc-BALF2–
infected allogeneic LCLs sharing individual HLA class I alleles with donor
CG as indicated.1613 Steven et al.
experiments deliberately focused on patients with the HLA-
B8 allele since this was the restriction element for the puta-
tive BZLF1 190-197 epitope identified by peptide stim-
ulation (30). Using ex vivo primary effectors, we observed
strong reactivity to BZLF1 190-197 in all three patients
tested, with levels of lysis being higher than those seen in
the same assays against two immunodominant latent cycle
epitopes, EBNA3A 325-333 and 158-166, again restricted
through HLA-B8 (Fig. 1, A–C). We have already shown
that these EBNA3A reactivities constitute .1% of the cir-
culating CD81 T cell pool in these particular patients (7),
and the implication is that the BZLF1 epitope-specific ef-
fectors are even more abundant. In this context, a recent
report has raised the possibility that EBV lytically infected
cells may be capable of inducing a superantigen-like prolif-
erative T cell response in vitro (40). So far, an equivalent
effect has not been observed in vivo, and indeed, the analy-
sis of Vb subset distribution and T cell receptor usage among
IM T cells strongly suggests that the CD81 T cell expan-
sions seen during primary EBV infection are antigen driven,
rather than superantigen driven (41). The present work in-
dicates that specific responses to EBV lytic as well as to
EBV latent antigens may contribute to these T cell expan-
sions.
It was possible to grow the lytic antigen-specific effectors
from IM blood in vitro by stimulating with the autologous
LCL, but the resultant polyclonal T cell line gradually be-
came dominated by CTLs recognizing the latent cycle
epitopes (Fig. 1, C–E). This is perhaps not surprising since
the stimulator LCLs are latently infected lines with ,5%
cells in lytic cycle and express the relevant BZLF1 antigen.
However, we found that the BZLF1-specific (and other
lytic antigen-specific) CTLs could be isolated away from
the latent cycle response by limiting dilution cloning of IM
T cells immediately ex vivo. This produced numerous
CTL clones from IM53, IM59, and IM63 which clearly
recognized the BZLF1 190-197 epitope peptide but, inter-
estingly, not target cells expressing BZLF1 from recombi-
nant vaccinia vectors (Fig. 2). Similar results were also ob-
served using LCL-stimulated memory CTL clones reactive
to the same BZLF1 epitope (data not shown). Such find-
ings were in contrast to the observations of Bogedain et al.
(30) who reported significant lysis of vacc-BZLF1–infected
targets by peptide-stimulated CTLs. Concerned by this dis-
crepancy, we went on to show that BZLF1 epitope-spe-
cific clones both from the primary and from the memory
response did recognize target cells expressing BZLF1 from
a transiently transfected plasmid vector (Figs. 2 and 7 A).
This strongly suggests that the CTL response seen in HLA-
B8–positive IM patients is indeed BZLF1-specific and that
processing of the BZLF1 190-197 epitope is somehow im-
paired in vaccinia-infected cells. There are other, albeit rare,
examples of inappropriate processing of vaccinia-expressed
antigens in the literature (42, 43). Therefore, we cannot
entirely discount the possibility that other lytic cycle epitopes,
perhaps other BZLF1 epitopes, have gone undetected in our
assays.
It is nevertheless clear that EBV infection induces abun-
dant CD81 CTL reactivities to a range of immediate early
and early lytic cycle proteins. Thus, even within the original
panel of three IM donors with immunodominant BZLF1-
specific responses, clonal analysis revealed additional sub-
dominant CTL reactivities against an HLA-A2.05–restricted
epitope in the immediate early protein BRLF1, against an
HLA-C6–restricted epitope in the early protein BMRF1,
and against an HLA-B18–restricted epitope in another
early protein, BMLF1 (Fig. 3 and data not shown). Extend-
ing the work to other IM patients with different HLA types,
we quickly identified individuals where BMRF1 (see IM55,
Fig. 6) and BMLF1 (see IM61 and IM69, Fig. 5) provided
immunodominant epitopes for the primary virus-induced
CTL response; in these cases, lysis of the relevant early lytic
cycle protein was easily detectable in ex vivo assays with
fresh IM effectors and the majority of the subsequently de-
rived CTL clones displayed the same specificity. The above
BMLF1 reactivity was particularly interesting since it was
restricted through the HLA-A02.01 allele, a molecule which
is consistently a weak restriction element for latent antigen-
specific responses (8, 9), yet which clearly can mediate a
strong response to lytically infected cells.
Table 1 presents a summary of the CTL reactivities iden-
tified in the course of this work. It should be stressed that
our study has concentrated on a limited number of viral
proteins, mainly of the immediate early and early subsets,
and is by no means a comprehensive survey of the full
range of potential target antigens expressed during the EBV
lytic cycle. Of the antigens tested, BZLF1 and BRLF1 are
the best known immediate early proteins and are expressed
at the very initiation of lytic cycle (25, 26). Together these
activate the expression of at least four of the early proteins
studied here, namely BMLF1, itself a transactivator (44),
BMRF1, a processivity factor involved in viral DNA repli-
cation (45), BHLF1, an early antigen EA-D component of
unknown function (46), and BHRF1, the viral homologue
of cellular Bcl-2 (47); the two other early proteins, BALF2
and BALF5, are also involved in viral DNA replication as
the major DNA binding protein and the viral DNA poly-
merase, respectively (23). The only evidence to date that
any of these early proteins contain T cell epitopes is the
identification of a HLA class II–restricted response to BHRF1
in an IM patient (48). It therefore seems significant that the
present analysis, though limited to a small number of do-
nors, nevertheless revealed responses to both of the imme-
diate early proteins and to three of the six early proteins
tested; these responses involved a minimum of eight differ-
ent epitopes and a minimum of nine different restriction el-
ements. Although most were identified through the analy-
sis of primary CTLs from IM patients, it is noteworthy that
lytic antigen-specific responses are also detectable in CTL
memory, even using the relatively inefficient strategy of in
vitro reactivation with the autologous LCL (Fig. 7). In this
context, a very recent paper from Scotet et al. (49) de-
scribed the isolation of BZLF1- and BMLF1-specific CTL
clones from synovial T cells infiltrating the affected joints1614 CTL Responses to Epstein-Barr Virus Lytic Cycle Antigens
of chronic rheumatoid arthritis patients. This further indi-
cates that lytic antigen-specific T cells are retained in long-
term virus carriers. It is also interesting to note that at least
3 of the 11 lytic antigen-specific responses described here
(including one of the immunodominant responses) were re-
stricted through HLA-C rather than HLA-A or -B alleles.
Interestingly, the peptide-stimulation work of Bogedain et
al. (30) suggested that BZLF1 also contained a C6-restricted
epitope that overlapped the B8 epitope sequence (such a
response was not seen in the present study), whereas an earlier
paper described alloreactive CTL clones which showed
fortuitous cross-recognition of EBV lytic antigen-positive
LCLs only if they expressed the HLA-C7 allele (50). The use
of HLA-C as a restriction element appears to be rare
amongst CTLs reactive to latent cycle antigens (24), possi-
bly reflecting the fact that HLA-C antigens are expressed at
only 5% of the level of HLA-A or -B on the latently-infected
LCL surface (51). The present findings raise the possibility
that HLA-C molecules may become more important for
antigen presentation as cells switch into lytic cycle.
The detection of such potent CTL responses to lytic cy-
cle antigens is an important step forward in our understand-
ing of EBV biology since it strongly suggests that foci of
EBV replication are subject to direct CTL control in vivo.
Thus, the fall in oropharyngeal virus shedding that occurs
with recovery from acute primary infection in IM (2) is
very probably brought about by the emerging lytic anti-
gen-specific CTL response. Likewise, the recrudescence of
virus replication seen in T cell–immunocompromised virus
carriers (10-12, 52) is probably a consequence of that re-
sponse being impaired. Although the present work does
not allow any firm conclusions to be drawn about the rela-
tive immunogenicity of different lytic cycle proteins, it
does clearly show that EBV immediate early and early pro-
teins are frequent targets for the virus-induced CTL re-
sponse. This is quite different from the situation in HSV
and CMV infection where particular virus-coded immedi-
ate early and/or early proteins either directly inhibit the
HLA class I pathway of antigen presentation (19, 20, 22)
or, as shown recently for a CMV immediate early protein,
are selectively protected from processing (53). As a conse-
quence, human CD81 CTL responses to these viruses are
markedly skewed towards structural proteins (tegument or
capsid components) that are delivered into infected cells by
the incoming virus particle (15, 16). The present evidence
suggests that immediate early and early proteins of the EBV
lytic cycle do not enjoy such immunological protection,
and hence, that EBV may not have evolved such effective
mechanisms of immune interference, at least not mecha-
nisms that are operative right from the initiation of lytic
gene expression. In this context, it is worth pointing out a
fundamental difference between the biology of g-herpesvi-
ruses such as EBV and that of a- and b-herpesviruses such
as HSV and CMV. For any herpesvirus, it is believed that
establishing a large pool of latently-infected cells in vivo in-
creases the subsequent chances of successful reactivation
and transmission to a new host (54, 55). g-herpesviruses are
able to achieve this in the absence of virus replication
through the virus-driven clonal expansion of latently in-
fected cells; a- and b-herpesviruses do not have this capac-
ity, and so the establishment and maintenance of their latent
reservoir is much more dependent upon lytic replication of
the virus during primary infection and/or recrudescence.
These latter agents may therefore have been under greater
evolutionary pressure to reduce their susceptibility to im-
mune detection during lytic cycle.
Table 1. EBV Lytic Antigen-specific CTL Reactivities
EBV antigen
Epitope
location, sequence HLA restriction CTL donor*
BZLF1 190-197, RAKFKQLL B8 IM53, IM59, IM63
BRLF1 ND A2.05 IM63
ND ND IM55
BMLF1 265-273, KDTWLDARM ND KG
280-288, GLCTLVAML A2.01 IM61, IM69
397-405, DEVEFLGHY B18 IM53
ND A24 IM55
BMRF1 86-100, FRNLAYGRTCVLGKE‡ C3 IM55
268-276, YRSGIIAVV C6 IM63
BALF2 ND B39 CG
ND C6 IM55
*Assays were carried out on ex vivo primary effectors from IM53, IM55, IM59, IM61, IM63, and IM69, on in vitro–expanded polyclonal primary
CTLs from IM53, IM59, and IM63, on in vitro–expanded primary CTL clones from IM53, IM55, IM59, IM63, and IM69, on in vitro–expanded
polyclonal memory CTLs from post-IM53, post-IM59, and post-IM63, and on in vitro–expanded memory CTL clones from post-IM63, KG, and CG.
‡Miminal epitope not yet defined.1615 Steven et al.
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